V451 vaccine

V451 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Other namesSARS-CoV-2 Sclamp
Routes of
administration
Intramuscular
Legal status
Legal status
  • Terminated

V451 was a COVID-19 vaccine candidate developed by the University of Queensland and the Australian pharmaceutical company CSL Limited. The vaccine candidate used the University of Queensland's molecular clamp technology[1] and the MF59 adjuvant.[2]

  1. ^ "UQ-CSL V451 Vaccine". www.precisionvaccinations.com. Archived from the original on 2020-12-19. Retrieved 2020-12-11.
  2. ^ Meneguzzi J (13 November 2020). "Why a COVID-19 vaccine could further imperil deep-sea sharks". National Geographic. Archived from the original on November 13, 2020.